JNJ-26489112 is under investigation in clinical trial NCT00579384 (A Study of the Effects of JNJ-26489112 on the Photic Induced Paroxysmal Electroencephalogram (EEG) Response in Patients With Photosensitive Epilepsy).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | JNJ-26489112 may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of JNJ-26489112. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of JNJ-26489112. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of JNJ-26489112. |
| Hydrocodone | JNJ-26489112 may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of JNJ-26489112. |
| Magnesium sulfate | The therapeutic efficacy of JNJ-26489112 can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | JNJ-26489112 may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | JNJ-26489112 may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of JNJ-26489112. |
| Mirtazapine | JNJ-26489112 may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of JNJ-26489112. |
| Orphenadrine | JNJ-26489112 may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | JNJ-26489112 may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of JNJ-26489112. |
| Pramipexole | JNJ-26489112 may increase the sedative activities of Pramipexole. |
| Ropinirole | JNJ-26489112 may increase the sedative activities of Ropinirole. |
| Rotigotine | JNJ-26489112 may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with JNJ-26489112. |
| Sodium oxybate | JNJ-26489112 may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | JNJ-26489112 may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of JNJ-26489112. |
| Thalidomide | JNJ-26489112 may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | JNJ-26489112 may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Mefloquine | The therapeutic efficacy of JNJ-26489112 can be decreased when used in combination with Mefloquine. |
| Mianserin | The therapeutic efficacy of JNJ-26489112 can be decreased when used in combination with Mianserin. |
| Orlistat | Orlistat can cause a decrease in the absorption of JNJ-26489112 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Topotecan | JNJ-26489112 may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with JNJ-26489112. |
| Tetracosactide | The risk or severity of liver damage can be increased when Tetracosactide is combined with JNJ-26489112. |
| Ethanol | JNJ-26489112 may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | JNJ-26489112 may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of JNJ-26489112. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when JNJ-26489112 is combined with Fluvoxamine. |
| Sertraline | The risk or severity of adverse effects can be increased when JNJ-26489112 is combined with Sertraline. |
| Zimelidine | The risk or severity of adverse effects can be increased when JNJ-26489112 is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when JNJ-26489112 is combined with Dapoxetine. |
| Seproxetine | The risk or severity of adverse effects can be increased when JNJ-26489112 is combined with Seproxetine. |
| Indalpine | The risk or severity of adverse effects can be increased when JNJ-26489112 is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when JNJ-26489112 is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when JNJ-26489112 is combined with Alaproclate. |
| Citalopram | The risk or severity of adverse effects can be increased when JNJ-26489112 is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when JNJ-26489112 is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when JNJ-26489112 is combined with Trazodone. |
| Paroxetine | The risk or severity of adverse effects can be increased when JNJ-26489112 is combined with Paroxetine. |
| Sibutramine | The risk or severity of adverse effects can be increased when JNJ-26489112 is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when JNJ-26489112 is combined with Nefazodone. |
| Escitalopram | The risk or severity of adverse effects can be increased when JNJ-26489112 is combined with Escitalopram. |
| Milnacipran | The risk or severity of adverse effects can be increased when JNJ-26489112 is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when JNJ-26489112 is combined with Desvenlafaxine. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when JNJ-26489112 is combined with Cocaine. |
| Quinidine | The therapeutic efficacy of JNJ-26489112 can be decreased when used in combination with Quinidine. |
| Zopiclone | The risk or severity of adverse effects can be increased when JNJ-26489112 is combined with Zopiclone. |
| Botulinum toxin type B | The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with JNJ-26489112. |
| Botulinum toxin type A | The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with JNJ-26489112. |
| Tryptophan | The risk or severity of CNS depression can be increased when Tryptophan is combined with JNJ-26489112. |
| Baclofen | Baclofen may increase the central nervous system depressant (CNS depressant) activities of JNJ-26489112. |
| Lorazepam | The risk or severity of CNS depression can be increased when Lorazepam is combined with JNJ-26489112. |
| Ethchlorvynol | The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with JNJ-26489112. |
| Succinylcholine | The risk or severity of CNS depression can be increased when Succinylcholine is combined with JNJ-26489112. |
| Reserpine | The risk or severity of CNS depression can be increased when Reserpine is combined with JNJ-26489112. |
| Eletriptan | The risk or severity of CNS depression can be increased when Eletriptan is combined with JNJ-26489112. |
| Enflurane | The risk or severity of CNS depression can be increased when Enflurane is combined with JNJ-26489112. |
| Temazepam | The risk or severity of CNS depression can be increased when Temazepam is combined with JNJ-26489112. |
| Reboxetine | The risk or severity of CNS depression can be increased when Reboxetine is combined with JNJ-26489112. |
| Butabarbital | The risk or severity of CNS depression can be increased when Butabarbital is combined with JNJ-26489112. |
| Butalbital | The risk or severity of CNS depression can be increased when Butalbital is combined with JNJ-26489112. |
| Methysergide | The risk or severity of CNS depression can be increased when Methysergide is combined with JNJ-26489112. |
| Cabergoline | The risk or severity of CNS depression can be increased when Cabergoline is combined with JNJ-26489112. |
| Phenytoin | The risk or severity of CNS depression can be increased when Phenytoin is combined with JNJ-26489112. |
| Topiramate | The risk or severity of CNS depression can be increased when Topiramate is combined with JNJ-26489112. |
| Clemastine | The risk or severity of CNS depression can be increased when Clemastine is combined with JNJ-26489112. |
| Venlafaxine | The risk or severity of CNS depression can be increased when Venlafaxine is combined with JNJ-26489112. |
| Etomidate | The risk or severity of CNS depression can be increased when Etomidate is combined with JNJ-26489112. |
| Morphine | The risk or severity of CNS depression can be increased when Morphine is combined with JNJ-26489112. |
| Talbutal | The risk or severity of CNS depression can be increased when Talbutal is combined with JNJ-26489112. |
| Pentobarbital | The risk or severity of CNS depression can be increased when Pentobarbital is combined with JNJ-26489112. |
| Valproic acid | The risk or severity of CNS depression can be increased when Valproic acid is combined with JNJ-26489112. |
| Zolmitriptan | The risk or severity of CNS depression can be increased when Zolmitriptan is combined with JNJ-26489112. |
| Codeine | The risk or severity of CNS depression can be increased when Codeine is combined with JNJ-26489112. |
| Dihydroergotamine | The risk or severity of CNS depression can be increased when Dihydroergotamine is combined with JNJ-26489112. |
| Amitriptyline | The risk or severity of CNS depression can be increased when Amitriptyline is combined with JNJ-26489112. |
| Tolcapone | The risk or severity of CNS depression can be increased when Tolcapone is combined with JNJ-26489112. |
| Hydromorphone | The risk or severity of CNS depression can be increased when Hydromorphone is combined with JNJ-26489112. |
| Olanzapine | The risk or severity of CNS depression can be increased when Olanzapine is combined with JNJ-26489112. |
| Cetirizine | The risk or severity of CNS depression can be increased when Cetirizine is combined with JNJ-26489112. |
| Protriptyline | The risk or severity of CNS depression can be increased when Protriptyline is combined with JNJ-26489112. |
| Trimethadione | The risk or severity of CNS depression can be increased when Trimethadione is combined with JNJ-26489112. |
| Clobazam | The risk or severity of sedation, somnolence, and CNS depression can be increased when Clobazam is combined with JNJ-26489112. |
| Chlorzoxazone | The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with JNJ-26489112. |
| Clozapine | The risk or severity of CNS depression can be increased when Clozapine is combined with JNJ-26489112. |
| Meprobamate | The risk or severity of CNS depression can be increased when Meprobamate is combined with JNJ-26489112. |
| Thiethylperazine | The risk or severity of CNS depression can be increased when Thiethylperazine is combined with JNJ-26489112. |
| Palonosetron | The risk or severity of CNS depression can be increased when Palonosetron is combined with JNJ-26489112. |
| Sulpiride | The risk or severity of CNS depression can be increased when Sulpiride is combined with JNJ-26489112. |
| Alprazolam | The risk or severity of CNS depression can be increased when Alprazolam is combined with JNJ-26489112. |
| Dexbrompheniramine | The risk or severity of CNS depression can be increased when Dexbrompheniramine is combined with JNJ-26489112. |
| Loxapine | The risk or severity of CNS depression can be increased when Loxapine is combined with JNJ-26489112. |
| Remoxipride | The risk or severity of CNS depression can be increased when Remoxipride is combined with JNJ-26489112. |
| Metocurine iodide | The risk or severity of CNS depression can be increased when Metocurine iodide is combined with JNJ-26489112. |